Trial Profile

A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Etoposide (Primary) ; Serplulimab (Primary) ; Atezolizumab
Indications Small cell lung cancer
Focus Adverse reactions; Registrational
Acronyms ASTRIDE
Sponsors Shanghai Henlius Biotech

06 Jun 2025 According to a Shanghai Henlius Biotech media release, Dr. David Gandara is the lead principal investigators of the ASTRIDE study.
23 Jan 2025 Planned primary completion date changed from 30 Apr 2025 to 30 Sep 2025.
20 Nov 2024 Planned primary completion date changed from 31 Oct 2024 to 30 Apr 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com